Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered ...

In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...

The pharmaceutical company Novo Nordisk has products sold under the Novolin brand name, and Eli Lilly ... (short-acting), NPH (intermediate-acting), or premixed NPH/regular insulin without a ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

New Delhi, Jan 9 (PTI) Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital ...

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs, and markets and 11 integrated data sets that span ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

In my opinion, Novo Nordisk (NVO) stock offers the former, while Eli Lilly (LLY) stock offers the latter. NVO stock may achieve better one-year returns due to its undervaluation, but LLY stock is ...